News

Tapazole (methimazole), a thyroid medication used to treat Graves’ disease, may in rare cases cause ANCA-associated vasculitis (AAV), a new patient study suggests. While the link between thyroid drugs and AAV is relatively common, few cases triggered by Tapazole have been described, and little is known about how…

In patients with ANCA-associated vasculitis (AAV), the reappearance of ANCA autoantibodies may work as a biomarker for predicting relapse, a new study suggests. Routine monitoring of ANCA antibody levels should be implemented in AAV patients in remission as a means to determine their risk of relapse, according to Japanese…

The protein myeloperoxidase (MPO) may increase the activation of neutrophils — key immune cells in ANCA-associated vasculitis — and heighten vascular injury in patients, a new study shows. The study, “Myeloperoxidase influences the complement regulatory activity of complement factor H,” was published in the journal Rheumatology. ANCA-associated vasculitis (AAV)…

A new case study supports previous findings that hydralazine — a medication used to treat high blood pressure — may cause ANCA-associated vasculitis with severe kidney injury, leading its researchers to recommend its use “generally be avoided.” A separate case report, published in March, linked this medication to end-stage kidney disease…

The National Organization for Rare Disorders (NORD) will celebrate the 35th anniversary of both the 1983 Orphan Drug Act and NORD’s founding at a dinner tonight in Washington, D.C. The 2018 Rare Impact Awards, to be held at the Andrew W. Mellon Auditorium, will be webcast via Facebook for those…